Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapies for the treatment and prevention of a broad spectrum of diseases. The company is headquartered in Beverly Hills, California.
| Revenue (TTM) | $11.13M |
| Gross Profit (TTM) | $-99.73M |
| EBITDA | $-133.07M |
| Operating Margin | 0.00% |
| Return on Equity | -73.70% |
| Return on Assets | -33.60% |
| Revenue/Share (TTM) | $0.24 |
| Book Value | $4.24 |
| Price-to-Book | 2.21 |
| Price-to-Sales (TTM) | 25.15 |
| EV/Revenue | 18.12 |
| EV/EBITDA | -2.73 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -7.90% |
| Shares Outstanding | $58.14M |
| Float | $42.60M |
| % Insiders | 9.44% |
| % Institutions | 74.10% |
Volatility is currently contracting
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript
Capricor Therapeutics NASDAQ: CAPR presented updated clinical data for deramiocel in Duchenne muscular dystrophy, or DMD, including two-year open-label extension results from its Phase III HOPE-3 study and additional statistical analyses submitted to the U.S. Food and Drug Administration.
-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year- -At 24 Months, Both Groups Showed Slower Decline in Upper Limb Function Than Natural History Predicts- -Data Included in Deramiocel BLA Major Amendment; PDUFA Target Action Date November 22, 2026- -Webinar Scheduled for October 7, 2026, at 1:00 p.m. ET in Collaboration with PPMD to Discuss the Data- SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive new data from its ongoing HOPE-3 open-label extension (OLE) study for its lead asset, Deramiocel, for the treatment of upper limb impairment in Duchenne muscular dystrophy (DMD).
NEW YORK--(BUSINESS WIRE)---- $CAPR #CAPR--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) and reminds investors of the September 28, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Geor.
NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ:CAPR) and certain of the company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.
LOS ANGELES, Sept. 28, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, Sept. 28, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
New York, New York--(Newsfile Corp. - September 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline. SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
New York, New York--(Newsfile Corp. - September 25, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Capricor and have suffered losses, you may CLICK HERE to contact us.
If you purchased or acquired Capricor securities between December 17, 2025 and July 26, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CAPR and any ticker you trade — then tracks every position and per-strategy win rate.
